Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT02153424

Early Post-marketing Study of Eliquis (Apixaban)

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
Bristol-Myers Squibb · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The primary objective of the study is to identify and describe any suspected (AEs) in all patients with NVAF treated with Apixaban, as a request of the National Center of Pharmacovigilance (CNFV) in Mexico.

Conditions

Interventions

TypeNameDescription
DRUGApixaban

Timeline

Start date
2014-04-01
Primary completion
2015-11-01
Completion
2015-11-01
First posted
2014-06-03
Last updated
2016-08-17

Locations

2 sites across 1 country: Mexico

Source: ClinicalTrials.gov record NCT02153424. Inclusion in this directory is not an endorsement.